Tyco's split raises queries on Bard deal
This article was originally published in Clinica
Executive Summary
Tyco International's unexpected plan to split into four businesses has complicated its proposed $3.1 billion merger with CR Bard. As a result of the split, Tyco's healthcare business, the second largest medtech company worldwide after Johnson & Johnson, will become an independent, "pure play" company.